Cited by 169Pneumocystis jirovecii pneumonia detection and treatmentPneumonia and Respiratory InfectionsAntibiotic Resistance in Bacteria

Pneumocystis carinii Dihydropteroate Synthase but Not Dihydrofolate Reductase Gene Mutations Correlate with Prior Trimethoprim‐Sulfamethoxazole or Dapsone Use

Ma, Liang, Borio, Luciana, Masur, Henry, Kovacs, Joseph A.·1999·The Journal of Infectious Diseases

Abstract

Recent studies of the human Pneumocystis carinii dihydropteroate synthase (DHPS) gene suggest that P. carinii is developing resistance to sulfamethoxazole (SMX) and dapsone.To explore whether P. carinii is also developing resistance to trimethoprim (TMP), the human P. carinii dihydrofolate reductase (DHFR) gene was cloned, DHFR and DHPS genes in 37 P. carinii isolates from 35 patients were sequenced, and the relationship between TMP-SMX or dapsone use and gene mutations was analyzed.The DHFR gene sequences were identical in all isolates except 1 with a synonymous substitution.In contrast, the DHPS gene sequences showed mutations in 16 of the 37 isolates; prior sulfa/sulfone prophylaxis was associated with the presence of these mutations ().In addition to suggesting that there is less selective P !.001pressure on DHFR than on DHPS, this study reinforces the hypothesis that mutations in the DHPS gene are likely involved in the development of sulfa resistance in P. carinii.The combination of trimethoprim (TMP) and sulfamethoxazole (SMX) serves as the first-line therapeutic and prophylactic regimen for pneumonia caused by Pneumocystis carinii, which remains a major opportunistic agent in patients infected with human immunodeficiency virus (HIV) and in other immunocompromised patients.This combination inhibits 2 key enzymes in folate metabolism.Dapsone is another commonly used prophylactic agent, and, like SMX, it targets the enzyme dihydropteroate synthase (DHPS), which catalyzes the condensation of para-aminobenzoic acid with 7,8-dihydropterin-pyrophosphate (DHPPP), forming 7,8-dihydropteroate.TMP acts on dihydrofolate reductase (DHFR), which catalyzes the reduction of dihydrofolate to tetrahydrofolate and is dependent on the reduced form of nicotinamide adenine dinucleotide phosphate.The widespread use of DHFR and DHPS inhibitors in antimicrobial chemotherapy has resulted in the emergence of antifolate drug resistance in numerous bacteria and some protozoa [1-10], raising concerns that similar resistance would develop

Integrity signals

Registry

Crossref · 10.1086/315148

Cites

41 of 41 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • Two studies have failed to demonstrate an association between the use of TMP-SMX for PCP prophylaxis in HIV-infected persons and the presence of DHFR gene mutations.

    “To date, two studies have failed to demonstrate an association between the use of TMP-SMX for PCP prophylaxis in HIV-infected persons and the presence of DHFR gene mutations (21,36).”
  • Sulfa medications appear to exert selective pressure on Pneumocystis, as the DHPS gene is more likely to display mutations in highly conserved regions in patients with PCP who have previously been exposed to sulfa medications.

    “Sulfa medications appear to exert selective pressure on Pneumocystis (18), as the DHPS gene is more likely to display mutations in highly conserved regions in patients with PCP who have previously been exposed to sulfa medications (19–25).”
  • Seven of the nine studies found that most HIV-infected patients with a diagnosis of PCP who had been prescribed TMP-SMX or dapsone for PCP prophylaxis had Pneumocystis that contained DHPS mutations (range 19%-80%).

    “Nevertheless, seven of the nine studies found that most HIV-infected patients with a diagnosis of PCP who had been prescribed TMP-SMX or dapsone for PCP prophylaxis had Pneumocystis that contained DHPS mutations (range 19%–80%, Table 2) (19–24,30).”
  • Several studies have consistently demonstrated a significant association between the use of TMP-SMX or dapsone for PCP prophylaxis in HIV-infected persons and the presence of DHPS gene mutations.

    “Several studies have consistently demonstrated a significant association between the use of TMP-SMX or dapsone for PCP prophylaxis in HIV-infected persons and the presence of DHPS gene mutations (Table 2) (19–25,30).”
  • Based on homology to the E. coli DHPS, these point mutations appear to be in an active site of the enzyme involved in substrate binding; thus, amino acid substitutions in these regions could result in structural changes that could interfere with substrate binding and enzyme activity.

    “Based on homology to the E. coli DHPS, these point mutations appear to be in an active site of the enzyme involved in substrate binding; thus, amino acid substitutions in these regions could result in structural changes that could interfere with substrate binding and enzyme activity (21).”

Cites

Flagged first, then by citations

3 of the 44 references couldn’t be matched to a known paper.

Cited by

Sorted by citations

Authors
Ma, L., Borio, L., Masur, H., & Kovacs, J. A.
Affiliations
National Institutes of Health (US)
Venue
The Journal of Infectious Diseases
Published
1999-12
Volume
180
Issue
6
Pages
1969-1978
ISSN
  • 0022-1899 (ISSN-L)
  • 1537-6613
OpenAlex
W1997907868
Cited by
169
References
44
Citations by year
2026: 1 · 2025: 2 · 2024: 2 · 2023: 2 · 2022: 2 · 2021: 4 · 2020: 2 · 2019: 6 · 2018: 5 · 2017: 3 · 2016: 7 · 2015: 6 · 2014: 5 · 2013: 6 · 2012: 6
FWCI
9.00
Type
journal article
Language
en
Open access
closed
Locations
  • The Journal of Infectious Diseases (publishedVersion)
  • PubMed (publishedVersion)
Topics
  • Health Sciences › Medicine › Epidemiology › Pneumocystis jirovecii pneumonia detection and treatment
  • Health Sciences › Medicine › Epidemiology › Pneumonia and Respiratory Infections
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Medicine › Antibiotic Resistance in Bacteria
Keywords
Pneumocystis carinii, dihydropteroate synthase, dihydrofolate reductase, sulfamethoxazole resistance, trimethoprim-sulfamethoxazole, dapsone, antifolate resistance, prophylaxis, HIV-associated pneumonia, opportunistic infections
MeSH terms
Amino Acid Sequence, Animals, Anti-Infective Agents, Cloning, Molecular, Dapsone, Dihydropteroate Synthase, Drug Resistance, Microbial, Genes, Fungal, Humans, Molecular Sequence Data, Mutation, Pneumocystis, Pneumonia, Pneumocystis, Tetrahydrofolate Dehydrogenase, Trimethoprim, Sulfamethoxazole Drug Combination, Sequence Alignment, Sequence Analysis, DNA, Rats

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review